AccuRna Inc. (Tokyo, JAPAN, “AccuRna”) today announced that the company enters into a Feasibility Study Agreement with Astellas Innovation Management LLC (Cambridge, MA, USA.) subsidiary of Astellas Pharma Inc for the use of delivery system of polymer micelle loaded with messenger RNA (mRNA) under pre-clinical development by AccuRna.

AccuRna will continue non-clinical development toward clinical application of delivery system of polymer micelle loaded with mRNA.